Skip to Content
Merck
  • Biological evaluation of a new family of aminosteroids that display a selective toxicity for various malignant cell lines.

Biological evaluation of a new family of aminosteroids that display a selective toxicity for various malignant cell lines.

Anti-cancer drugs (2012-03-01)
Hajer Jegham, René Maltais, Jenny Roy, Charles Doillon, Donald Poirier
ABSTRACT

This study investigated the antineoplasic potential of a new family of aminosteroids. The antiproliferative activity of seven 5α-androstane-3α,17β-diol derivatives selected from a screening study was measured on nine cancerous cell lines (HL-60, K-562, LNCaP, PC-3, Shionogi, MCF-7, MDA-MB-231, BT-20, and OVCAR-3) and two normal cell lines (peripheral blood lymphocytes and WI-38). The aminosteroids efficiently inhibited the cell growth of seven cancer cell lines [inhibitory concentration (IC(50)) values=0.2-6.4 µmol/l] and showed weak toxicity on normal cell lines. Two representative aminosteroids were tested and found to induce apoptosis and a G0/G1 cell cycle block in HL-60-treated cells, but not terminal myeloid differentiation. By a nuclear morphology analysis with fluorescence microscopy, typical apoptotic morphological changes were exhibited by treated cells. One aminosteroid tested in vivo (xenograft model) reduced the breast cancer (MCF-7 cells) tumor growth induced in nude mice. Furthermore, the information gathered suggests that this family of aminosteroids induced growth inhibition cells by arresting the cell cycle and triggering apoptosis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
5α-Androstane-3α,17β-diol